BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Market Closed - Borsa Italiana 16:04:59 2024-06-27 EDT | ||
| 2.8 EUR | -6.98% |
|
| Current month | +3.73% | ||
| 1 month | -1.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 2.8 | -6.98% |
| 24-06-26 | 3.01 | +0.67% |
| 24-06-25 | 2.99 | +1.01% |
| 24-06-24 | 2.96 | -0.34% |
| 24-06-21 | 2.97 | +2.24% |
Real-time Borsa Italiana
Last update June 27, 2024 at 04:04 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| S35236 | |
| ISIN | DE000SW8WBH1 |
| Date issued | 2024-04-15 |
| Strike | 10,075 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.21 € |
|---|---|
| Lowest since issue | 1.096 € |
| Spread | 0.08 € |
| Spread % | 2.82% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
158.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.04%
- Stock Market
- Certificates
- S35236 Certificat
